AlzeCure will participate and present at Swiss Nordic Bio 2026 in Zurich on 1 October.
CEO Martin Jönsson is scheduled to provide an updated view following recently signed collaboration and outlicensing agreements with US-based Eli Lilly and Denmark-based QuantumCell ApS relating to AlzeCure’s Alzheimer’s programs, and to hold one-on-one meetings with investors and potential partners.
The event is organized by Business Sweden and Pareto Securities with Swiss and Austrian partners and is expected to gather around 200 participants, including more than 70 investors, feature over 40 company presentations and host more than 400 one-on-one partnering meetings.
AlzeCure is a Swedish biotech developing small-molecule drug candidates for central nervous system diseases, including Alzheimer’s disease and pain, and is advancing programs across its NeuroRestore, Alzstatin and Painless research platforms.
